Arcutis Biotherapeutics (ARQT) said Monday it submitted a supplemental new drug application to the US Food and Drug Administration for Zoryve cream 0.05% for the treatment of mild to moderate atopic dermatitis in children aged 2 to 5 years.

The cream demonstrated consistent, rapid relief and good tolerability in prior trials, according to the company.